We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Atox Bio

News List

Atox Bio Announces Exercise by BARDA of Next Option Period for NSTI Treatment americanpharmaceuticalreview
June 20, 2019
Atox Bio announced the Biomedical Advanced Research and Development Authority (BARDA) has exercised the next option on a performance-based contract with for the development of Reltecimod in patients with Necrotizing Soft Tissue Infections (NSTI).
Atox Bio Announces Chief Commercial Officer Appointment americanpharmaceuticalreview
February 18, 2019
Atox Bio announced the appointment of Robert Greif as Chief Commercial Officer. In this newly created position, Greif will be responsible for building the commercial organization and pre-commercial activities for Reltecimod....